Anaphylaxis News and Research

RSS

Anaphylaxis is an acute multi-system severe type I hypersensitivity reaction. Due in part to the variety of definitions, between 1% and 15% of the population of the United States can be considered "at risk" for having an anaphylactic reaction if they are exposed to one or more allergens. Of those people who actually experience anaphylaxis, up to 1% may die as a result.

Food allergies may lead to 'kissing' allergies

Even brushing your teeth or waiting hours after eating may not prevent some partners of people with food and medicine allergies from triggering an allergic reaction through a kiss, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov.11-16.

17 Nov 2010

50% of nut allergic patients not able to recognize nut types

Only half of people with peanut or tree nut allergies know what the nut they are allergic to looks like, according to a study presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix Nov. 11-16. Researchers assembled a nut display that held peanuts and nine tree nuts in 19 different forms. A worksheet, which listed the items, was completed by 1,105 participants 6 years or older. Responses were analyzed based on demographics, presence or absence of food allergies, and occupational history.

15 Nov 2010

Study finds children more likely to be allergic to amoxicillin

Children are more likely to have an allergy to amoxicillin than adults, according to a study presented at the American College of Allergy, Asthma and Immunology annual meeting in Phoenix Nov. 11-16. Amoxicillin is a form of penicillin.

15 Nov 2010

Combination of Chinese herbal formula and conventional treatments may help treat food allergies

Complementary and alternative medicine may give allergy and asthma sufferers new options for treating symptoms, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov. 11-16. Allergists discussed how herbal treatments may be integrated into conventional allergy treatments, including a novel Chinese herbal formula for treating all types of food allergies.

15 Nov 2010

Dyax to present data of KALBITOR inhibitor for Angioedema at ACAAI Meeting

Dyax Corp. today announced that an abstract featuring KALBITOR (ecallantide) data was accepted for oral presentation at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting held November 11-16, at the Phoenix Convention Center in Phoenix, AZ. Two additional abstracts were selected as poster sessions.

15 Nov 2010

Plant-based respiratory allergies on the rise due to climate change

Bad news for 35 million allergy sufferers - ragweed, fungal spores and poison ivy are thriving due to rising carbon dioxide levels. At the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov. 11-16, allergists and scientists discussed the effects of rising CO2 levels and a changing climate on plant biology and public health.

12 Nov 2010

ACAAI scientific meeting to discuss pediatric allergies

Your child may be allergic to your holiday pumpkin pie, according to allergists at the annual scientific meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Phoenix, Nov. 11-16. Hot topics discussed in pediatric allergies include pumpkin and caterpillar allergies, and outgrowing childhood allergies.

12 Nov 2010

Scientists to present new findings from NIAID-funded research at ACAAI Annual Meeting

The 2010 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) brings together leading allergists and immunologists from around the world.

12 Nov 2010

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.

8 Nov 2010

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix Pharmaceuticals, Inc. today announced that the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of hepatic encephalopathy, or HE.

1 Nov 2010

FDA approves Teflaro for treatment of community-acquired bacterial pneumonia

Forest Laboratories, Inc. announced today that Teflaro(ceftaroline fosamil), a broad-spectrum bactericidal cephalosporin with activity against both gram-positive and gram-negative microorganisms, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of community-acquired bacterial pneumonia (CABP), including cases caused by Streptococcus pneumoniae bacteremia, and acute bacterial skin and skin structure infection (ABSSSI), including cases caused by methicillin-resistant Staphylococcus aureus (MRSA).

30 Oct 2010

Innovative program for new graduate doctors to ensure safety prescription

A new software based program has recently been created for new graduate doctors to ensure they prescribe safely from day one on the wards.

26 Oct 2010

Baxter announces launch of GLASSIA in the U.S.

Baxter International Inc. today announced the commercial launch of GLASSIATM [Alpha1-Proteinase Inhibitor (Human)] in the United States. GLASSIATM is the first available ready-to-use liquid alpha1-proteinase inhibitor (Alpha1-PI) and is indicated as a chronic augmentation and maintenance therapy in adults with emphysema due to congenital deficiency of alpha-1 antitrypsin (AAT), an under-diagnosed hereditary condition characterized by a low level of alpha-1 protein in the blood.

From Baxter International Inc. 26 Oct 2010

Salix presents two Phase 3 pivotal clinical trials data for non-C IBS at ACG Meeting

Salix Pharmaceuticals, Ltd. today announced the presentation of two analyses of data from its Phase 3 pivotal clinical trials, TARGET 1 and 2, demonstrating a 14-day course of XIFAXAN 550 mg (rifaximin) taken three times daily achieved adequate relief of symptoms of non-constipation irritable bowel syndrome (non-C IBS) in a significantly greater proportion of patients compared with placebo.

19 Oct 2010

Revised guidelines for first aid

The American Red Cross and American Heart Association today announced changes to guidelines for administering first aid. Among the revisions are updated recommendations for the treatment of snake bites, anaphylaxis (shock), jellyfish stings and severe bleeding. The First Aid Guidelines are being published in Circulation: Journal of the American Heart Association.

19 Oct 2010

Study: 2.5% of Americans have food allergy

An estimated 2.5 percent of Americans — 7.5 million people — have at least one food allergy and young black children with asthma appear to be at the highest risk, according to findings from what is believed to be the largest food allergy study to date. The research was conducted by investigators at Johns Hopkins Children's Center, the National Institutes of Health and other institutions.

18 Oct 2010

Biogen, Elan announce clinical utility data of two-step ELISA to detect anti-JCV antibodies

Biogen Idec and Elan Corporation, plc today announced data further supporting the potential clinical utility of an investigational assay that detects anti-JC virus (JCV) antibodies in human plasma or serum.

18 Oct 2010

Food allergies are becoming more common in U.S. children

The scary reality is that food allergies are becoming more and more common in the United States. In the last 10 years there has been an 18 percent increase in children with food allergies. In fact, one in 22 children has a food allergy. That means most likely there is at least one child in each classroom with a food allergy. Halloween parties and trick or treating are just a few of the end of fall activities that can heighten the danger for kids with food allergies.

13 Oct 2010

Alkermes' VIVITROL medication for treatment of opioid dependence

Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved VIVITROL(naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence, following opioid detoxification.

13 Oct 2010

ACE educational program launched to promote awareness on anaphylaxis

Many of the approximately 1,500 deaths in the U.S. each year due to anaphylaxis, a sudden serious allergic reaction, could be prevented if more people knew the symptoms and the immediate treatment needed to survive.

12 Oct 2010